5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Fermenta Biotech Ltd.

•
fermentabiotech.comBSE: 506414NSE: FERMENTA
Market Cap₹ 1,398 Cr.
Current Price
High / Low₹ 580 / 249
Stock P/E23.1
Book Value₹ 140
Price to Book2.27
Dividend Yield0.79 %
ROCE22.0 %
ROE18.4 %
Face Value₹ 5

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Chemicals: 98.2% • Properties: 1.8%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Promoters have been increasing their shareholding - up 2.0pp over 2 years
  • Operating margins have improved to 19.2% from 7.7%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.95x)
  • Company generates healthy free cash flow
  • Company comfortably covers its interest (8.6x coverage)
  • Company has a consistent dividend-paying track record

CONS

  • Recent results are weak - TTM profit is down 47.0% versus prior year
  • Recurring exceptional / one-off items are inflating headline profit
  • Company has delivered a poor sales growth of 6.8% over past five years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.FERMENTA475.0523.111398.120.799.53-55.87121.82-10.6021.9914.82
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
825799977895156140136130137122122
727174927776103103108104112102112
Operating Profit11-1425511953372827252010
OPM %13.27%-24.46%25.38%5.52%1.02%19.76%34.04%26.41%20.72%20.45%18.17%16.45%8.47%
2-6353324951144
Interest5453344333333
Depreciation6666666665555
Profit before Tax2-29161-61245322824172615
Tax %0.00%-0.00%37.83%884.62%-0.00%5.92%16.43%-4.19%23.10%25.12%31.24%29.03%35.12%
Net Profit0000-61138332218121910
0.64-9.893.41-2.41-2.013.9412.7111.797.496.484.363.513.40

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
164303405293377399350336469525511
152212269229295336332308359424429
Operating Profit1291135648362182811110182
OPM %7.29%30.11%33.44%21.95%21.89%15.62%5.20%8.31%23.54%19.21%16.03%
311271488-204122925
Interest1014212019182117151311
Depreciation1012121520262825242221
Profit before Tax-676129435227-51-10839682
Tax %-48.86%27.82%8.39%-37.08%17.63%44.10%-3.56%-143.18%8.18%26.71%29.44%
Net Profit-855118604315-53-24767058
EPS-49.8236.750.000.0015.695.33-17.70-7.9926.3525.03—
Dividend Payout %-5.02%1.70%0.98%24.23%15.85%23.34%-7.06%-15.65%9.49%14.98%—

COMPOUNDED SALES GROWTH

10 Years:
13%
5 Years:
7%
3 Years:
15%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
10%
3 Years:
—

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
—

RETURN ON EQUITY

10 Years:
16%
5 Years:
4%
3 Years:
11%
Last Year:
18%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2018

Aug 8

1:1

Stock Split & inter alia, to consider: a) Split/Sub-division of shares of the Company b) Issue of bonus equity shares c) Amendment to the Capital Clause of the Memorandum of Association, consequent to the proposed split/subdivision of shares and issue of bonus equity shares & Bonus issue

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital22514141414141514
Minority Interest281100-0-1-3-4-4-6
142122245289334343288262348389
90178212224232244244151118119
Trade Payables27404356626546657777
163128-8808851688036
Total Liabilities307385532576722753640556633630
9097104129263231238263223217
Capital Work in Progress43216753304221613
927672003000
39518812916215913087124153
00000007095112
Cash & Bank2339133453458607241
1631991531461992991687410394
Total Assets307385532576722753640556633630

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
4781234876531131054193
Cash from Investing7-101-97-44-42-26-55-15-0-43
Cash from Financing-128912-47-1-22-41-91-51-42
-4476-5720-419-1-108

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
62.0662.0662.0664.0964.0964.0964.0964.0964.09
0.000.050.020.020.020.020.020.020.13
0.000.000.000.000.000.000.000.000.04
Government0.000.000.000.000.000.000.000.000.00
37.9437.8937.9135.8935.8935.8935.8935.8935.75

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08
Updates

2026-09-08 - Fermenta Biotech Limited has informed the Exchange about Press Release regarding exclusive Licence Agreement with Vellore Institute of Technology ( VIT ), Vellore for Vitamin B12 Fortification Technology.

2026-09-04
Updates

2026-09-04 - Fermenta Biotech Limited has informed the Exchange regarding Resubmission of the outcome filed on August 11, 2026, in machine readable format, in response to the e-mail received dated September 03, 2026.

2026-08-27
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-27 - Fermenta Biotech Limited has informed the Exchange about Schedule of investor(s) meeting(s) to held on September 03 2026.

2026-08-26
Copy of Newspaper Publication

2026-08-26 - Fermenta Biotech Limited has informed the Exchange about Copy of Newspaper Publication pertaining to notice for Special Window for Transfer and Dematerialisation of Physical Securities.

2026-08-17
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-17 - Fermenta Biotech Limited has informed the Exchange about Schedule of investor(s) meeting to be held on August 21, 2026.

2026-08-17
Credit Rating- Revision

2026-08-17 - Fermenta Biotech Limited has informed the Exchange about Revision in Credit Rating.

2026-08-12
Copy of Newspaper Publication

2026-08-12 - Fermenta Biotech Limited has informed the Exchange about Copy of Newspaper Publication pertaining to unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026.

2026-08-11
General Updates

2026-08-11 - Fermenta Biotech Limited has informed the Exchange about Declaration of Voting Results of the 74th Annual General Meeting.

2026-08-11
Shareholders meeting

2026-08-11 - Fermenta Biotech Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 11, 2026. Further, the company has informed the Exchange regarding voting results.

News

Recent coverage and analyst commentary for FERMENTA

Loading news…

🤖

AI Stock Analyst

Fermenta Biotech Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login